Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review

ConclusionsDofetilide was well tolerated in this group of patients with AF and HCM and it facilitated management of AF in 21/25 (84%) patients. Further research is needed to assess the safety and efficacy of dofetilide in order develop evidence‐based guidelines for the pharmacological management of AF in this population.This article is protected by copyright. All rights reserved

Source: Pacing and Clinical Electrophysiology : PACE - February 1, 2018 Category: Cardiology Authors: JoEllyn C. Moore, Lena Trager, Lucille E. Anzia, Walid Saliba, Mohamed Bassiouny, Mandeep Bhargava, Mina Chung, Milind Desai, Ross Garberich, Harry Lever, Bruce D. Lindsay, Jay Sengupta, Patrick Tchou, Oussama Wazni, Bruce L. Wilkoff Tags: ELECTROPHYSIOLOGY Source Type: research